A personalized mRNA vaccine paired with Keytruda may help keep skin cancer from returning after surgery, a large clinical ...

Merck and Moderna's mRNA cancer vaccine hit its Phase 3 trial endpoint, showing improved recurrence-free survival in melanoma ...

An experimental vaccine kept melanoma from returning or spreading in people at high risk of the skin cancer recurring, ...

Moderna and Merck say their new mRNA vaccine, when combined with Keytruda, has shown promise in preventing the skin cancer ...

U.S. pharmaceutical firms Merck and Moderna announced Wednesday encouraging results from a trial of their experimental ...

Earlier this year, we discussed a collaborative effort between Merck and Moderna, two large biotechnology pharmaceutical ...

Melanoma, one of the most dangerous and aggressive forms of skin cancer, is seeing a monumental shift in therapeutic research ...

Merck and Moderna say their personalized cancer vaccine reduced melanoma recurrence and spread in a Phase 3 trial.

At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning ...